Access to high quality, fully annotated serum, tissue and blood samples are
available for Genomic and Proteomic Research
DALLAS-FORT WORTH, Texas, Jan. 9 /PRNewswire/ -- Oncology Metrics, a business that develops products and services to help accelerate advancements in the treatment of cancer, and Cureline Inc., a global biosample management company dedicated to innovation in human tissue research, have reached an agreement to collaborate on oncology biospecimen procurement and management. The goal of this collaboration is to facilitate the collection and preservation of high quality pre-treatment and post-treatment samples with maximum efficiency.
Human specimens are used extensively in drug discovery and development for characterization of mutations and expression profiles that define severe diseases such as cancer, asthma, rheumatoid arthritis, diabetes and other conditions, and that could be used for developing personalized therapeutics, vaccines and diagnostics. One of the limiting steps in the research and development process is getting access to well-preserved clinically defined samples from patients with detailed and accurate health records. The collaboration between Oncology Metrics' sample procurement network Cure Pace and Cureline will improve the access of industrial and academic researchers to high quality biospecimens.
Olga Potapova, Ph.D., Founder and CEO of Cureline, views the collaboration as "a unique opportunity to provide to academia and the industry cancer biospecimens collected from diverse ethnic background populations through Cureline's clinical network in Eastern Europe and Asia and through the Oncology Metrics' clinical network in the USA."
Commenting on the collaboration, Warren Dodge, President and CEO of
Oncology Metrics said "by leveraging the scientific expertise and access to
tissue and our domestic access to serum and fresh whole blood, we become a
much better resource for the scientis
|SOURCE Oncology Metrics|
Copyright©2008 PR Newswire.
All rights reserved